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Abstract
Purpose: In multi-stage radiotherapy, a patient is treated in several stages
separated by weeks or months. This regimen has been motivated mostly by radio-
biological considerations, but also provides an approach to reduce normal tissue
dose by exploiting tumor shrinkage. The paper considers the optimal design of
multi-stage treatments, motivated by the clinical management of large liver tu-
mors for which normal liver dose constraints prohibit the administration of an
ablative radiation dose in a single treatment.
Method: We introduce a dynamic tumor model that incorporates three factors:
radiation induced cell kill, tumor shrinkage, and tumor cell repopulation. The
design of multi-stage radiotherapy is formulated as a mathematical optimization
problem in which the total dose to the normal tissue is minimized, subject to
delivering the prescribed dose to the tumor. Based on the model, we gain insight
into the optimal administration of radiation over time, i.e. the optimal treatment
gaps and dose levels.
Results: We analyze treatments consisting of two stages in detail. The anal-
ysis confirms the intuition that the second stage should be delivered just before
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the tumor size reaches a minimum and repopulation overcompensates shrinking.
Furthermore, it was found that, for a large range of model parameters, approxi-
mately one third of the dose should be delivered in the first stage. The projected
benefit of multi-stage treatments in terms of normal tissue sparing depends on
model assumptions. However, the model predicts large dose reductions by more
than a factor of two for plausible model parameters.
Conclusions: The analysis of the tumor model suggests that substantial re-
duction in normal tissue dose can be achieved by exploiting tumor shrinkage via
an optimal design of multi-stage treatments. This suggests taking a fresh look at
multi-stage radiotherapy for selected disease sites where substantial tumor regres-
sion translates into reduced target volumes.
1 Introduction
Radiotherapy planning aims at maximizing the chance of cancer cure while minimiz-
ing the risk of side effects in normal tissues. This goal is approached by optimizing
the dose distribution in both space and time. The spatial aspect of radiotherapy plan-
ning amounts to adequate target volume delineation and subsequent optimization of
the spatial dose distribution, e.g. through intensity-modulated radiotherapy (IMRT).
The temporal aspect of treatment planning considers the question how radiotherapy is
administered over time.
In this work, we consider a specific application of temporal optimization in radiotherapy.
The approach aims at reducing normal tissue dose by exploiting tumor shrinkage over
the course of therapy. The motivational example comes from a patient who presented
with a very large liver tumor. It was not possible to deliver an ablative radiation dose
without exceeding commonly used dose-volume constraints for the non-involved liver.
The patient was treated at our institution in two stages, with a four months gap in
between. By waiting for 4 months after the first stage, we could take advantage of
significant tumor shrinkage during the gap period, in this case down to less then 50%
of the original volume. This allowed us to shrink the treatment fields at the second
stage of treatment, thereby reducing the dose burden on surrounding healthy organs.
A general concern with this unconventional treatment regimen is of course the growth
of the residual tumor during the treatment gap period. The purpose of this paper is to
understand the potential advantage of this approach by introducing a simple biological
model that takes the tradeoff between tumor shrinkage and tumor cell repopulation into
account. We also wish to maximize the advantage by optimizing the time gap and the
dose delivered at each treatment stage.
The biological motivation for exploiting tumor shrinkage in multi-stage treatments stems
from the fact that the standard radiation treatment regime, in which a fixed dose of
radiation is delivered consecutively and in the same way over a number (5-40) of treat-
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ment days, is inefficient. Even after only one treatment fraction of 2 Gy or more, the
number of active tumor cells is typically already reduced by about a factor of 2. In
all subsequent fractions, we therefore treat mostly tumor cells that are already dead.
Near the end of the treatment course, only a tiny number of active tumor cells remains.
Tumor shrinkage, which may occur because macrophages clear out the dead tumor cells
over time, provides an opportunity to avoid treating the dead cells and thereby increase
the efficiency of the use of radiation substantially.
While we have found one paper that shrinks the field size due to tumor regression
[1], it seems that the primary motivation for the rest period is to allow the normal
tissue to recover, rather than waiting for the tumor to regress further. The Nobel
lecture by Hounsfield in 1979 [2] describes in qualitative terms what we model in this
paper. Nowadays, modern technologies may allow us to clinically implement a multi-
stage radiotherapy approach to exploit tumor shrinkage. Advances in imaging allow for a
better delineation of the tumor. In addition, the precision in dose delivery has improved
substantially with the development of intensity-modulated radiotherapy, proton therapy,
and cone beam imaging for patient setup.
Review of multi-stage radiotherapy: The idea of dividing a treatment into two or
more phases with a rest period of typically 2-4 weeks has been around for a long time.
Such treatments have been called split-course radiotherapy and have been discussed as
early as 1935 [3]. The most common argument for a split-course is better preservation
of normal tissue due to its faster regeneration capability compared to tumors in the rest
period. Others include better treatment efficacy due to improved tumor vascularization
and increased tumor re-oxygenation after the rest period. The rationale has therefore
been purely radiobiological and has possibly kept the rest period short and in the order
of 2-4 weeks. The efficacy of split-course therapy has been assessed by many random-
ized trials and retrospective studies [4]. There have been studies using split-course for
tumors of the head and neck [3], lung [5, 1], and pelvis [6]. However, to the best of our
knowledge, there do not seem to have been any for liver tumors. Several randomized
studies in the 1960s through 1980s had indicated split-course radiotherapy to be no
worse than conventional continuous treatment [4]. However, later retrospective studies
have indicated that split-course treatments are less effective, especially for fast growing
tumors such as head and neck [7, 8]. Further discussion about previous split-course
radiotherapy studies can be found in [4]. These previous works, however, have not used
a smaller field size at the second stage, meaning there was no physical dose reduction
for the normal tissue.
Previous work on temporal optimization: Previous work on optimizing radiation
delivery over time has been performed in the context of fractionation. The radiobio-
logical basis of fractionation are repair processes, which happen within hours after ir-
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radiation. Thus, work on the optimization of fractionation schemes is mostly based on
the linear-quadratic cell survival model and extensions thereoff. It is known that time
dependencies such as incomplete repair in between fractions and accelerated repopula-
tion give rise to nontrivial nonuniform fractionation schemes [9, 10, 11, 12, 13]. Even
though our paper is also concerned with temporal optimization of radiotherapy, it is
based on tumor shrinkage which happens on a time scale of several months. Instead,
fractionation is based on repair processes that happen on a time scale of hours. Thus,
these two applications are based on distinct processes and should be distinguished.
Contribution and organization of this paper: The paper has two specific ob-
jectives: First, we want to estimate the amount of normal tissue sparing that can be
expected from exploiting tumor shrinkage in a multi-stage treatment. Second, we want
to gain insight into the optimal treatment regimen, i.e. the optimal doses delivered in
each stage and the optimal time gaps between stages. The rest of this paper is organized
as follows: Section 2 introduces the clinical case and treatment strategy that served as
the motivation for this study. In section 3 we develop the model of tumor growth and
response to radiation. We further formulate the design of multi-stage treatments as
a mathematical optimization problem. Sections 4 and 5 analyze treatments with two
stages in detail. In section 6 we discuss the benefit of adding a third stage, and obtain
qualitative insight into the optimal N -stage treatment. Finally, section 7 summarizes
the results and discusses the clinical application of multi-stage radiotherapy, focusing
on liver metastases.
2 Clinical motivation: large liver tumors
The most commonly used dosing strategy for liver stereotactic body radiation therapy
(SBRT) is based on dose-volume constraints for the non-involved liver. Thereby, the
prescription dose depends on the amount of radiation the non-involved liver receives,
and is limited such that the normal liver constraints are fulfilled. With this paradigm,
as the ratio of tumor to non-involved liver increases, the amount of radiation that can
be given decreases. This leads to a paradox: larger tumors are treated with lower doses.
Thus, in patients with very large tumors, SBRT with the current dosing paradigms
is unlikely to be ablative and cannot offer potentially curative therapy. Thus, from a
clinicians perspective, a patient with a large solitary liver lesion cannot be cured, in
spite of the absence of extrahepatic disease. Therefore, there is a clinical motivation to
find alternative strategies for dealing with large lesion cases.
2.1 Case report
The patient who motivated this work presented with a very large liver tumor (a metastatic
lesion originating from chemo-refractory colorectal cancer). The initial target volume in
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the first treatment stage was assessed using 4D CT, resulting in an internal gross target
volume (IGTV) of 1218 cc in size (which incorporated a peak-to-peak motion of 4.15
mm as defined at the fiducials). In comparison, the total volume of normal appearing
liver was 870 cc. Thus, the tumor mass accounted for 58% of the total liver volume.
The patient was treated in two stages separated temporally by a period of four months.
Figure 1 shows the radiotherapy planning CT for the first stage (a) and the second stage
(b). Until the most recent follow-up visit (6 months after the second stage), the liver
lesion remains stable.
(a) Stage 1 (b) Stage 2
Figure 1: Planning CT image of the patient for the first treatment stage (a) and the
second stage (b) four months later. The corresponding CT slices for the two time points
are chosen based on the bony anatomy of the spine. The red contour shows the GTV,
the green contour corresponds to the liver.
Both treatment stages used a dose painting strategy in which the planning target volume
was subdivided into two parts: a low dose PTV was constructed via a 3 mm isotropic
expansion of the IGTV; a high dose PTV was constructed by a 1 cm contraction of the
low dose PTV. This allowed for a dose reduction to normal radiosensitive tissue adjacent
to the target volume while delivering a high SBRT dose to the interior target volume. In
the first stage the low dose PTV was treated to 18 Gy in 3 fractions while the high dose
PTV was treated to a total of 36 Gy in 3 fractions concurrently. After the four month
intermission, the patient returned to be rescanned and treated using the new imaging
information. The physician-defined IGTV was 499 cc (37% of total liver volume), and
thereby substantially smaller than in the first stage (see figure 1b). The prescribed dose
to the low dose PTV for stage two was 20 Gy in 3 fractions, while the high dose PTV
received 30 Gy in 3 fractions. Deformable registration was performed in order to assess
the cumulative dose to secondary organs at risk, such as the spinal cord and the kidneys.
Through the dose painting approach, the mean dose to the non-involved liver (i.e. total
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liver without GTV) was reduced to 10.8 Gy in the first stage, and 13.3 Gy in the second
stage.
3 Model for staged tumor irradiation
3.1 Model of tumor growth and radiation response
In this section, we formulate a model that describes the temporal evolution of the tumor
size due to growth and radiation response. We assume that the size of the tumor is
influenced by three factors:
1. Radiation therapy: The radiation effect on the tumor is described by exponential
cell kill such that the surviving fraction of tumor cells after irradiation is given by
e−αd. Here, d is the total physical dose delivered, and α is an effective radiosensi-
tivity parameter which incorporates the fractionation scheme to be used1.
2. Repopulation: Surviving tumor cells after radiotherapy are assumed to proliferate
exponentially. After a time t, the number of active tumor cells increases by a
factor of et/τg where τg is the time constant for tumor repopulation.
3. Tumor shrinkage: Tumor cells that are lethally damaged during irradiation are
slowly removed. It is assumed that this process is described by an exponential
decay [14, 15]. After a time t the fraction of dead tumor cells that remain is given
by e−t/τs where τs is the time constant for tumor shrinkage.
The entire treatment consists of N treatment stages which we index by i. At each
stage, a dose di is delivered to the tumor. After completion of stage i, a treatment gap
ti is imposed before the next stage is delivered. At the beginning of treatment stage i,
the tumor consists of both viable tumor cells and dead tumor cells that have not been
removed yet. We denote the number of viable tumor cells by ai and the number of dead
tumor cells by zi. The discrete time evolution equations for both cell compartments is
governed by state update equations. Based on the above assumptions, the number of
viable tumor cells at the next stage is given by
ai+1 = ai exp(−αdi)︸ ︷︷ ︸
cell kill
exp(ti/τg)︸ ︷︷ ︸
repopulation
(1)
1Assuming that the dose d is delivered using n fractions and a dose per fraction df , the linear-
quadratic cell survival model can be written as S = exp(−n(α0df + β0d
2
f )) = exp(−αd) where α =
α0(1+df/(α0/β0)) is an effective radiosensitivity parameter that depends on the α/β-ratio and increases
linearly with the dose per fraction. The envelope of the log cell survival curve thus becomes linear in
the total dose.
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The change in the number of dead tumor cells is given by
zi+1 = zi exp(−
ti
τs
)︸ ︷︷ ︸
further decay
+ ai (1− exp(−αdi)) exp(−
ti
τs
)︸ ︷︷ ︸
decay of cells killed in stage i
(2)
where the first term describes the further decay of the dead tumor cells zi that were
present at stage i, and the second term describes the decay of the tumor cells killed in
stage i. The tumor volume vi, i.e. the current tumor volume in stage i, is given by the
sum of viable and dead tumor cells:
vi = ai + zi (3)
In this paper, we are primarily interested in relative changes. Therefore, we normalize
ai and zi to the initial number of viable tumor cells. Consequently, vi represents the
relative tumor volume in stage i compared to the initial tumor volume. The initial state
is thus given by
a1 = 1 z1 = 0 v1 = 1 (4)
3.2 Normal tissue sparing factor
For the initial treatment stage in which dose d is delivered to the tumor, the normal
tissue receives an inhomogeneous dose distribution with mean dose δd. We refer to
δ < 1 as the initial sparing factor for the normal tissue. For our work, we have to
make assumptions on how the sparing factor decreases while the tumor shrinks. We
assume that the sparing factor decreases proportionally with the area of the radiation
field needed to treat the tumor. In turn, the area of the radiation fields decreases
quadratically with the diameter of the tumor, while tumor volume decreases cubically.
This leads to the following generic model for the sparing factor δi in stage i:
δi = δ · v
2/3
i (5)
This generic model has limitations since it does not take the specific patient geometry
and the beam arrangement into account. Therefore, we use this generic model in the
main text of the manuscript, but in section 5.3 we discuss the sensitivity of our results
with respect to deviations from this model.
3.3 Optimization of multi-stage treatments
In the optimal design of general N stage treatments, we aim to determine the doses di
and the time gaps ti for each stage. The goal consists of minimizing the cumulative mean
dose delivered to the healthy tissue, while assuring that a desired surviving fraction of
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viable tumor cells is achieved by the end of treatment2. This can be formulated as the
following optimization problem:
minimize
di≥0, ti≥0
N∑
i=1
δidi (6)
subject to
N∑
i=1
di = D
P +
∑N−1
i=1 ti
ατg︸ ︷︷ ︸
repopulation
(7)
ai+1 = ai exp(−αdi) exp(
ti
τg
) (8)
zi+1 = zi exp(−
ti
τs
) + ai (1− exp(−αdi)) exp(−
ti
τs
) (9)
vi = ai + zi (10)
δi = δv
2/3
i (11)
a1 = 1, z1 = 0 (12)
The objective function (6) to be minimized represents the cumulative mean normal tissue
dose over the duration of the treatment. The constraint in equation (7) determines the
total dose delivered to the tumor: DP denotes the tumor dose that would be prescribed in
a single stage treatment; the second term represents the extra dose needed to compensate
for tumor repopulation over the entire course of treatment, which is linear in the total
treatment time. The constraint (7) ensures that the N stage treatment results in the
same fraction of surviving tumor cells as a single stage treatment with prescription dose
DP . Equations (8-11) determine the time evolution of the tumor state as described in
section 3.1. It should be noted that the initial sparing factor δ factors out of the objective
function. Thus, the optimal dose levels di and optimal time gaps ti are independent of
the initial sparing factor δ. In order to make all results independent of the initial sparing
factor δ, we define the relative cumulative normal tissue dose as
dL =
∑N
i=1 δidi
δDP
=
∑N
i=1(vi)
2/3di
DP
(13)
which is the cumulative normal tissue dose for an N -stage treatment divided by the
normal tissue dose for a single stage.
2In this formulation, we assume a homogeneous dose prescribed to the tumor, and we consider the
mean dose in the normal tissue. Considering the mean dose is appropriate for tumors embedded in
a dose-limiting organ, such as liver tumors. In addition, these two quantities do not rely on dose
accumulation on a voxel-by-voxel basis, which would be difficult to perform due to tumor shrinkage
and large deformations of the normal tissue.
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3.4 Model parameters
It is evident that the model parameters are uncertain and vary between patients and
tumor histologies. In order to obtain insight into the optimal design of multi-stage
treatments, we study a nominal set of parameters in sections 4 and 6. The parameter
values are summarized in table 1. In section 5 we perform a sensitivity analysis to study
two-stage treatments over a wide range of parameters.
The set of nominal model parameters are motivated by the liver tumor case presented in
section 2. The prescription dose is set to DP = 60 Gy. The tumor shrinkage parameter
τs was set to 4 months based on the fact that in our clinical example case the tumor
shrank within 4 months to less than 50% of its original size. The repopulation parameter
τg was also set to 4 months based on reports from the literature that both primary liver
tumors and metastases exhibit a relatively long tumor doubling time of around 3 months
or more [16, 17, 18]. Note that the tumor doubling time equals ln 2 τg = 0.7 τg. The
effective radiosensitivity parameter α was set to α = 0.4 Gy−1. This is consistent with
estimated radiosensitivity parameters of primary liver tumors [19] and a wide spectrum
of other primary tumors [20, 21].
Time constant for tumor shrinkage τs 4 months
Time constant for repopulation τg 4 months
Effective radiosensitivity α 0.4 Gy−1
Prescription dose DP 60 Gy
Table 1: Nominal model parameters used in this paper.
4 Two-stage treatments
We begin by studying a two-stage treatment by setting N = 2 in the general model
(6-12), which may represent the most important application in practice. In this case,
the number of decision variables is reduced to two, namely
1. the dose d1 delivered to the tumor in the first stage, and
2. the time gap t1 between the first and second stage.
Given that we are considering only two stages, the dose in the second stage, d2, is
determined by the constraint (7) and given by
d2 =
t1
ατg
+DP − d1 (14)
We want to determine the time gap t1 and the doses d1 and d2 such that the cumulative
normal tissue dose after the end of the second stage is minimized. Since we have only
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two free decision variables, d1 and t1, we can simply plot the cumulative normal tissue
dose as a function of these. The result is shown in figure 2a for the set of parameters
in table 1. It is seen in figure 2a that the cumulative normal tissue dose has a unique
minimum corresponding to the following treatment regimen:
Dose levels: d1 = 18.3 Gy, d2 = 50.7 Gy
Time gap: t1 = 14.4 months
Relative cumulative normal tissue dose: dL = 0.42.
In our model, it is optimal to deliver a relatively small initial dose of 18.3 Gy. After a
time gap of 14.4 months a larger dose of 50.7 Gy is delivered. The cumulative normal
tissue dose for this treatment regimen is 42% of the dose in a single stage treatment,
thus representing a substantial normal tissue dose reduction.
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(a) relative normal tissue mean dose dL(d1, t1)
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Figure 2: (a) Cumulative normal tissue mean dose dL as a function of initial dose d1
and time gap t1 for the parameters in table 1; (b) Relative tumor volume v2(d1, t1) in
the second stage of the treatment. The black dot marks the location of the optimal
solution.
4.1 Qualitative analysis
We can further qualitatively interpret figure 2a in order to discuss the different compet-
ing factors that determine the optimal treatment regimen. For that purpose, figure 2b
shows the relative tumor volume v2(d1, t1) in the second stage.
Limit of long time gaps and small initial doses: It is intuitive that a treatment is
suboptimal if the tumor volume in the second stage is larger than in the first stage. This
is the case for low doses d1 and long time gaps t1 where the tumor volume is dominated
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by repopulation. In figure 2b we plot the line where v2(d1, t1) = 1 (corresponding
to δ2(d1, t1) = δ). This line (lowermost dark red line) limits the range of reasonable
treatment regimens away from large time gaps and low initial doses. The line in (d1, t1)
space where v2(d1, t1) = 1 is approximately a straight line with slope 1/(ατg), which
corresponds to the extra dose added for repopulation per unit time interval.
Optimal initial dose: For any given time gap t1, increasing the initial dose d1 de-
creases the surviving fractions of tumor cells. However, for large d1, further increases do
not translate into noticeable reduction in the tumor volume, which becomes dominated
by the removal of dead cells. This is seen as the vertical isolines in figure 2b. On the
other hand, a large initial dose means that the dose in the second stage is small. Thus,
the ability to take advantage of a lower sparing factor is reduced, and as seen in figure
2a, the mean normal tissue dose increases (approximately linearly) for large initial doses.
Thus, the initial dose d1 has to be large enough to provide tumor shrinkage, but small
enough to capitalize on the tumor shrinkage in the second stage. For our model, the
optimal trade-off is achieved if approximately 30% of the dose is delivered in the first
stage.
Optimal time gap: For small time gaps, the treatment regimen is suboptimal because
the tumor is still in its shrinking phase. The dose reduction in the second stage can be
improved by waiting longer for the tumor to shrink further. For small time gaps, this
advantage compensates for the adverse effect of the extra dose added to compensate for
repopulation. Intuitively, we expect the time gap should be chosen such that the second
stage is delivered when the tumor size reaches the minimum. It is straightforward to see
that this is strictly true if no extra dose is added for repopulation in (14). Otherwise,
the second stage should be delivered when the tumor is still in its shrinking phase as
shown in appendix A. The numerical results indicate (figure 2b) that the optimal time
to deliver the second stage is approximately when the tumor size reaches the minimum.
5 Sensitivity analysis
The predicted benefit of a two-stage treatment over a single-stage treatment depends on
model assumptions and parameters. In this section, we study the benefit of two-stage
treatments over a wide range of parameter values and consider the dependence of the
initial dose d1 and the time gap t1 on parameter values.
5.1 Repopulation and shrinkage
Fast tumor regression (small τs) is in favor of two-stage treatments. Thus, decreasing τs
would further increase the projected benefit of two-stage treatments, and suggest shorter
treatment breaks t1. Likewise, slow repopulation (large τg) favors two-stage treatments.
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On the other hand, fast tumor cell repopulation (small τg) works against the benefit of
two-stage treatments. Decreasing τg leads to shorter time gaps t1, and higher cumu-
lative normal tissue dose dL. Figure 3a shows the cumulative normal tissue dose as a
function of d1 and t1 for a repopulation time constant of τg = 2 months (twice the value
compared to figure 2). As a consequence, the slope of the line v2(d1, t1) = 1, which limits
beneficial treatment regimens away from large t1 and small d1, is doubled. This pushes
the optimal treatment to a shorter time gap t1 = 10.8 months and a slightly higher
initial dose d1 = 20.9 Gy, and increases the achievable cumulative normal tissue dose to
dL = 0.55 (compared to t1 = 14.4, d1 = 18.3, and d
L = 0.42 for the nominal parameters).
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Figure 3: Cumulative normal tissue mean dose dL as a function of initial dose d1 and
time gap t1: (a) for τg = 2 months; (b) for τg = 2 months, Vmin = 0.1, and q = 0.16.
The remaining parameters are chosen according to table 1.
In the tumor model, the treatment break t1 only appears in ratios t1/τs and t1/τg.
Thus, if time is measured in units of the repopulation constant τg, it becomes apparent
that the results for d1 and d
L are independent of the absolute values of τs and τg, and
only depend on the ratio of shrinkage and repopulation time constant τs/τg
3. Figure
4 shows the optimal dose delivered in stage one and the cumulative normal tissue dose
as a function of the ratio τs/τg. There is a wide range of parameter values for which
there is a benefit for two-stage treatments. Only for very fast repopulation, if τg is
approximately 11 times smaller than τs, the optimal treatment break becomes zero and
a single stage treatment becomes optimal. When repopulation is approximately 5 times
faster than shrinkage, the dose delivered in stage one has a maximum at 45% of the
prescription dose. When τs and τg are equal, approximately 30% of the dose is delivered
in stage one. For very fast shrinkage, approximately 20% of the dose is delivered in the
first stage.
3This also means that, for any fixed ratio τs/τg, the treatment break t1 increases linearly with the
absolute values of the time constants, but the proportionality constant depends on τs/τg.
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Figure 4: Dependence of the cumulative normal tissue dose dL (red line) and the optimal
initial dose d1/D
P (black line) on the ratio of shrinkage and repopulation time constant.
The remaining parameters are chosen as in table 1.
5.2 Radiosensitivity
Figure 5 shows the dependence of the normal tissue dose and the decision variables
on the radiosensitivity parameter α. The benefit of a two stage treatment decreases
for radioresistent tumors, which is expected because a given initial dose d1 leads to
less tumor shrinkage that can be exploited in the second stage. However, only for
radiosensitivity parameters of α ≈ 0.07 Gy−1 (corresponding to a surviving fraction of
0.87 at 2 Gy) a single stage becomes optimal. In addition, the optimal initial dose d1
depends only mildly on the radiosensitivity parameter.
5.3 Normal tissue sparing factor model
In the main text of this paper, we used the generic model in equation 5 for the relation
of the sparing factor δi and reduction in tumor volume vi. This model does not account
for the patient specific geometry of tumor and dose-limiting normal tissue, nor does it
take into account the beam arrangement. For a patient at hand, the relation between
δi and vi may be different. In order to assess the benefit of two-stage treatments for a
wider range of sparing factor models, we consider the generalized model
δi = δ · v
q
i (15)
where q = 2/3 corresponds to the model used throughout the paper. For smaller val-
ues of the exponent, the reduction in the sparing factor as a function of tumor volume
becomes more shallow around the initial sparing factor δ (see figure 6). Thus, values
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Figure 5: Dependence of the cumulative normal tissue dose dL (red line), the optimal
time gap t1 (blue line), and the optimal initial dose d1/D
P (black line) on the radiosen-
sitivity parameter α. The remaining parameters are chosen as in table 1.
q < 2/3 correspond to situations that are less favorable for two-stage treatments. For
q → 0 there is no reduction in the sparing factor until the tumor volume becomes zero.
Figure 7 shows the decision variables t1 and d1 and the cumulative normal tissue dose
as a function of the exponent q. As expected, the benefit of two-stage treatments
decreases for smaller exponents because a tumor volume reduction translates into only
a minor sparing factor reduction. However, two-stage treatments remain optimal up to
exponents of q ≈ 0.05. In addition, the dose delivered in the first stage depends only
mildly on the sparing factor model.
5.4 Minimum target volume
The above results assume that the target volume in the second stage is determined by
the number of viable and dead (but not yet removed) tumor cells. In reality, the residual
target volume may be larger if the location of the remaining viable cells is uncertain.
To address this concern, we considered a modified version of equation (5) in which the
sparing factor is calculated according to
δ2(d1, t1) = δ [v2(d1, t1) + (1− v2(d1, t1))Vmin]
2/3 (16)
where Vmin ∈ [0, 1] is the relative minimum target volume that is to be treated in the
second stage. Vmin can be thought of as a clinical target volume (CTV) containing ar-
eas of potential microscopic disease beyond a visible mass of necrosis and residual tumor.
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Figure 6: Sparing factor reduction vq as a function of volume reduction v for different
exponents q. A value of q = 0.05 corresponds approximately to the sparing factor model
at which a single stage treatment becomes optimal for the parameters in table 1.
Figure 8 shows the cumulative normal tissue dose and the decision variables as a function
of the relative minimum target volume Vmin. As expected, the advantage of a two-stage
treatment in terms of normal tissue sparing decreases with increasing Vmin. Further-
more, the optimal time gap decreases. A minimum target volume results in a minimum
sparing independent of the time gap and the initial dose. Hence, prolonging the treat-
ment through large time gaps t1 approximately leads to a linear increase t1δV
2/3
min/ (ατg)
of the mean normal tissue dose. Nevertheless, figure 8 shows a substantial projected
benefit of a two-stage treatment for large residual target volumes. For example, a fairly
large residual target volume of 20% yields a relative normal tissue dose of dL = 0.61.
Only in the case that 90% of the initial target volume is not subject to shrinkage, a
single stage treatment becomes optimal (figure 8). The optimal initial dose d1 depends
only mildly on the minimum target volume.
Clearly, single stage treatments become optimal if all parameters are chosen as to work
against the benefit of two-stage treatments, i.e. fast repopulation, large residual treat-
ment volume, small sparing factor reduction. This is illustrated in figure 3b for the
parameters τg = 2 months, Vmin = 0.1, and q = 0.16. In this case, a two-stage treat-
ment is still optimal (t1 = 4.76 months, d1 = 15.5 Gy), but the benefit is negligible
(dL = 0.98). Further worsening one of the parameters eliminates the local minimum
and makes single stage treatments more favorable.
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Figure 7: Dependence of the cumulative normal tissue dose dL (red line), the optimal
time gap t1 (blue line), and the optimal initial dose d1/D
P (black line) on the sparing
factor model parameter q. The remaining parameters are chosen as in table 1.
6 Multi-stage treatments
In this section we discuss treatment schedules consisting of more than two stages. In
section 6.1, we start by discussing the benefit of adding a third treatment stage half way
into the optimal two-stage treatment. In section 6.2, we consider the optimal three-stage
treatment for optimal time gaps. In section 6.3 we obtain insight into quasi-continuous
treatments in which the patient is irradiated in many stages at regular time intervals.
6.1 Adding a third stage at fixed time intervals
We consider the set of nominal parameters and fixed time gaps t1 = t2 = 7.2 months,
such that the total treatment time t1 + t2 remains equal to the optimal two stage
treatment (14.4 months). The optimal dose levels for the three treatment stages are
as follows:
Dose levels: d1 = 11.6 Gy, d2 = 9.8 Gy, d3 = 47.6 Gy
Time gaps: t1 = t2 = 7.2 months
Relative cumulative normal tissue dose: dL = 0.35
It is observed that adding a third stage half way into the optimal two-stage treatment
yields a moderate improvement. The relative cumulative normal tissue dose decreases
from 42% to 35%. Figure 9 shows the cumulative normal tissue dose as a function of the
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Figure 8: Dependence of the cumulative normal tissue dose dL (red line), the optimal
time gap t1 (blue line), and the optimal initial dose d1/D
P (black line) on the minimum
target volume Vmin. The remaining parameters are chosen as in table 1.
dose levels in stage 1 and 2. In comparison to the optimal two-stage treatment, we note
that the dose delivered in the last treatment stage remains approximately the same.
Instead, the dose that is delivered initially in the two-stage treatment is partly shifted
into the intermediate stage of the three-stage treatment. For a fixed dose in the final
stage, the distribution of dose over stage 1 and 2 is driven by two competing objectives:
(1) delivering a large dose in stage 1 minimizes the tumor volume in the final stage, and
(2) any dose delivered in the second stage can take advantage of the tumor shrinkage
that occurs over the first time gap. This leads to the compromise found in the solution
above.
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Figure 9: Cumulative normal tissue mean dose for a 3-stage treatment as a function of
the dose levels d1 and d2 for the parameters in table 1 and fixed time gaps of 7.2 months.
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6.2 The optimal three-stage treatment
We now consider the optimal three-stage treatment by determining the optimal doses
d1 and d2 as well as the optimal time gaps t1 and t2. The optimal treatment regimen
was obtained by exhaustive search over the four parameters. The following treatment
regimen was obtained:
Optimal dose levels: d1 = 11.9 Gy, d2 = 15.4 Gy, d3 = 46.7 Gy
Time gaps: t1 = 8.7 months, t2 = 13.7 months
Relative cumulative normal tissue dose: dL = 0.32
It is observed that optimizing the time gaps of a 3-stage treatment further prolongs
the treatment. However, the projected benefit compared to the regimen in section 6.1
is small. A summary of the results above for single stage, two-stage and three-stage
treatments is provided in table 2.
d1(Gy) t1(months) d2(Gy) t2(months) d3(Gy) d
L
Single stage 60.0 – – – – 1.00
2-stage 18.3 14.4 50.7 – – 0.42
3-stage (t1 = t2) 11.6 7.2 9.8 7.2 47.6 0.35
3-stage (optimal) 11.9 8.7 15.4 13.7 46.7 0.32
Table 2: Comparison of optimal dose levels and time gaps for two- and three-stage
treatments in comparison with a single stage treatment. The reduction of dose dL to
healthy tissue is shown in the last column.
6.3 Quasi-continuous treatments
Finally we now consider a treatment regimen in which the patient is treated quasi
continuously, i.e. at relatively short regular intervals for a fixed maximum treatment
period. We consider fixed time gaps ti = t for all of N treatment stages such that the
dose levels di are the only decision variables. To optimize the dose levels, we use dynamic
programming as described in appendix B. To illustrate the main findings regarding quasi-
continuous treatment regimens, we consider an 8 stage treatment with fixed time gaps of
slightly over 2 months, such that the total treatment time is 14.4 months (corresponding
to the time gap of the optimal two-stage treatment). The optimal dose levels are shown
in figure 10. The treatment starts with a dose of 7 Gy in the first stage. Between stage
2 and 7, a relatively low maintenance dose of approximately 3 Gy is delivered. Most
of the dose (44 Gy) is delivered in the last stage when the tumor size is smallest. The
treatment regimen shown in figure 10 yields a cumulative normal tissue dose of 0.33%.
This is slightly lower than the three-stage treatment in section 6.1 for the same overall
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treatment duration. Similar treatment schedules (i.e. a sizeable initial dose, followed
by a low maintenance dose, and a high final boost dose) have been observed over a wide
range of model parameters.
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Figure 10: Dose levels for the optimal 8-stage treatment delivered over 14.4 months (i.e.
the time gap between two consecutive stages is slightly over 2 months).
7 Discussion
Multi-stage radiotherapy has long been considered as a potential treatment regimen.
Motivations for multi-stage radiotherapy include: First, radiobiological reasons, e.g. the
regeneration of healthy tissues over the treatment break; and second, physical reasons,
e.g. better normal tissue sparing due to a shrinking field size. Previous clinical trials on
multi-stage radiotherapy were mostly motivated by radiobiological reasons. Since these
trials failed to establish a benefit, multi-stage radiotherapy is rarely applied in current
clinical practice. However, advances in imaging as well as advanced treatment techniques
such as IMRT and SBRT, suggest taking a fresh look at multi-stage treatments for
selected sites due to physical reasons.
7.1 Main findings of the paper
Two-stage treatments: We analyzed a model of a tumor which incorporates three
factors: radiation-induced cell kill, tumor shrinkage, and tumor repopulation. Our
analysis has focused on two-stage treatments. The model allows us to estimate the
potential normal tissue dose reduction achievable by treating a smaller tumor in the
second stage. In addition, the optimal initial dose that should be delivered in the first
treatment stage and the optimal time gap between first and second stage are obtained. It
is shown that there is potential for normal tissue dose reduction for a wide range of model
parameters. For favorable parameters, the projected benefit of two-stage treatments is
substantial and exceeds a normal tissue dose reduction by more than 50%. The model
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parameters will be uncertain and dependent on the treatment site. This applies to both
the radiobiological parameters for radiosensitivity, repopulation and shrinkage, as well
as the parameters to relate tumor shrinkage to normal tissue sparing. A sensitivity
analysis with respect to the parameters revealed that the initial dose delivered in the
first treatment stage is approximately 30% to 45% of the prescribed tumor dose that
would be delivered in a single-stage treatment. The second stage should be delivered
just before the tumor size reaches a minimum.
Insight into the optimal quasi-continuous treatment: We obtained insight
into the optimal quasi-continuous treatment in which the patient is treated at short
regular time intervals for a fixed total treatment time. Qualitatively, the model suggests
a treatment policy in which the treatment is initiated with a moderate initial dose,
followed by an approximately constant low maintenance dose, and a final dose boost in
the last stage. The projected benefit of adding additional treatment stages is relatively
small compared to the benefit of two stages over a single stage. The small projected
benefit of additional stages, together with potential concerns regarding the validity of the
tumor response model for very small dose levels in each stage, suggest that a two-stage
approach is a reasonable consideration for clinical implementation.
7.2 Potential applications for multi-stage radiotherapy
Our work in this paper is primarily motivated by patients with large liver tumors as
illustrated in section 2. However, with continuing improvements in image guidance and
dose delivery precision, the potential of multi-stage radiotherapy (motivated by tumor
shrinkage) could be reevaluated. This analysis can be guided by the following criteria
that favor multi-stage treatments:
1. The disease site exhibits significant tumor regression, which translates into a
smaller treatment volume in the second phase. This suggests treatment sites
where a large portion of the target volume represents gross disease that is subject
to regression. In contrast, treatment sites where most of the target volume repre-
sents potential microscopic disease (where no reduction in the target volume can
be exploited) are less promising candidates for multi-stage treatments.
2. The adverse effects of protracting the treatment are small. This suggests tumors
that have relatively slow tumor repopulation rates, such as liver cancers [16], as po-
tential candidates. In contrast, tumors exhibiting fast repopulation (or accelerated
repopulation) are less likely to be candidates for multi-stage therapy. In addition,
for some tumor entities, potential metastatic spread of disease may represent an
additional concern for prolonging treatment.
It is evident that for any treatment site that is a potential candidate for multi-stage
radiotherapy based on tumor shrinkage, there will be other clinical factors which play
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a role in the design of the treatment scheme. In particular, the potential for normal
tissue dose reduction due to tumor shrinkage has to be weighed against the possible risks
of prolonging the treatment. This would have to be assessed in a disease site specific
manner, which is outside the scope of this paper. Thus, this paper demonstrates the
potential for normal tissue dose reduction by exploiting tumor shrinkage in multi-stage
treatments, suggesting that this should be considered as a factor in designing treatment
schemes. However, to devise a concrete application, a broader view involving all clinical
factors has to be taken.
7.3 Application to liver tumors
Since this work was motivated by the management of large liver tumors we provide a
more detailed discussion regarding this potential application. For large liver tumors,
multi-stage radiotherapy is motivated by several factors:
1. Dose-volume constraints for the non-involved liver prevent the delivery of an ab-
lative radiation dose in a single course.
2. Regrowth of normal liver occurs over the treatment break. As a consequence the
total dose that can be delivered to the liver is increased.
3. Normal tissue dose can be reduced by treating a smaller tumor in the second stage
as discussed in this paper.
The development of the liver after the first course of radiation will play an important
role in designing split-course treatments. That includes the timescale on which regrowth
of normal liver occurs as a function of dose delivered in the first stage, the reirradiation
tolerance of the liver as a function of the time gap, as well as the spatial location of
functional and non-functional liver. In addition, the combination of radiation with other
therapies has to be considered. For example, the question arises whether chemotherapy
should be continued over the treatment break.
In order to further evaluate the role of normal tissue dose reduction due to tumor shrink-
age, the relation between tumor shrinkage v and the mean liver dose reduction dL has
to be studied for realistic patient geometries and beam arrangements. The analysis
of follow-up imaging data of previously treated liver patients may provide a way to
characterize this relation. Follow-up imaging data acquired approximately at 3 months
intervals post treatment provide snapshots of the patient geometry for shrunken tumors.
Thus, a treatment planning study involving these different time points may allow us to
assess the dependence of dL on v. Likely, this relation will depend on tumor size and
location within the liver.
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For the nominal parameters in table 1, the model predicts a very long treatment break
of 14 months. Whether this is realistic for liver metastasis can be questioned in light
of the observed median survival and the time to progression in these patients, which
is comparable to this time span [22, 23]. This may indicate that the nominal model
parameters are not adequate for most liver patients. In addition, the model does not
account for effects such as varying radiosensitivity of tumor cells or accelerated repop-
ulation. The analysis of follow-up imaging may provide information regarding tumor
shrinkage and regrowth over time. However, in practice, two-stage treatments would
not depend on an accurate prediction of the treatment gap. Instead, repeated imag-
ing of the patient (e.g. every 1-2 months) can monitor tumor shrinkage over time. If
tumor regrowth is observed earlier than expected, the treatment break can be shortened.
The model further predicts that the dose delivered in the first stage should be in the
order of 30% to 45% of the prescription dose. For large liver tumors, which was the
original motivation for this work, the interpretation of this result should take into ac-
count that the desired prescription dose is higher than what can be safely delivered in a
single stage treatment. For example, if the cumulative prescription dose to a large liver
tumor is 60 Gy, it may be that only 30 Gy can be delivered in the first stage to max out
dose-volume constraints for the liver. In this case, the model suggests a moderate dose
reduction to 20 to 25 Gy in the first stage. Thus, the dose reduction in the first stage
is less than it may appear.
8 Conclusion
The treatment of large liver tumors with radiation faces the problem that dose-volume
constraints for the non-involved liver prevent the application of a curative radiation dose
in a single stage. This motivates the exploration of alternative treatment regimens in
which the patient is irradiated in multiple stages seperated by months. In this paper, we
assess the potential benefit of exploiting tumor shrinkage that occurs during the treat-
ment break. The reduced target volume in the second stage allows for smaller radiation
fields, which translates into a dose reduction in the healthy tissue. We are concerned
with temporal optimization of multi-stage radiotherapy. By studying a dynamic model
of tumor growth and response to therapy, we obtain insight into the optimal treatment
schedule, i.e. the optimal doses delivered in each stage and the treatment breaks in
between stages. For a two-stage treatment, the second stage should be delivered just
before the tumor size reaches its minimum and repopulation overcompensates shrinkage.
The model suggests that the dose delivered in the first stage should approximately be
one third of the prescribed dose. Furthermore, we applied dynamic programming in or-
der to determine the optimal treatment schedule in a quasi-continuous treatment where
the patient is treated many times at regular time intervals. In this case, the optimal
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treatment policy consists of a moderate initial dose, followed by a low maintenance dose,
and a large boost dose in the last stage. The true benefit of exploiting tumor shrinkage
in multi-stage treatments will have to be assessed using patient data while taking the
patient and beam geometry into account. However, the large reduction in normal tissue
dose by more than a factor of two observed in the model suggests that tumor shrinkage
may be an important factor in designing multi-stage treatments.
A On the optimal time gap
We consider a two-stage treatment and proof that the second stage should be delivered
just before tumor size reaches a minimum. To that end, we calculate the partial deriva-
tive of the normal tissue dose dL(d1, t1) in equation (13) with respect to the time gap
t1. Using equation (14) for the dose in the second stage, and noting that the dose in the
first stage is independent of t1, we have
∂dL
∂t1
=
1
δDP
[
∂δ2(d1, t1)
∂t1
d2(d1, t1) +
δ2(d1, t1)
ατg
]
(17)
At the optimal time gap we have ∂dL/∂t1 = 0. Since δ2(d1, t1) > 0 it follows that
∂δ2(d1, t1)/∂t1 has to be negative in order to fulfill that condition. This means that the
second stage is to be delivered while the tumor is still in the shrinking phase. Intuitively
this makes sense since there is a price for delaying the treatment due to the repopulation
dose correction. However, as seen in figure 2b this effect is small; the second stage is
delivered when the tumor size is very close to its minimum.
B Dynamic programming formulation
In this section, we provide a dynamic programming (DP) formulation used to obtain the
optimal N -stage treatment regimen for fixed time gaps ti = t. For a general introduction
to DP we refer the reader to [24]. We make the associations below:
Control variables: The control variable at each stage is the dose di delivered to
the tumor.
Cost function: The cost incurred at stage i is given by the dose δidi delivered
to the healthy tissue. The goal is minimize the cumulative normal tissue dose.
State variables: At every stage, the state of the tumor is fully described by
the number of viable tumor cells ai and the number of dead tumor cells zi. The
corresponding state dynamics is given in equations (1) and (2). We can further
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note that the number of living cells is uniquely determined by the cumulative dose
delivered to the tumor until stage i via the equation
ai = exp
(
−α
i−1∑
j=1
dj
)
exp
(
(i− 1)t
τg
)
(18)
and does not depend on the history of dose delivery. Thus, to characterize the
state, it is sufficient to keep track of the cumulative tumor dose and the number
of dead tumor cells.
Since we only have two continuous state variables and one continuous control variable,
the DP problem can be solved through discretization and by applying the standard DP
algorithm. In this work, we use a discretization of 0.1 Gy in the control variables and the
cumulative dose state; for the relative number of dead tumor cells we use a discretization
of 0.001.
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